Urinary Retention Therapeutics Market Report 2026

Urinary Retention Therapeutics Market Overview

• Urinary Retention Therapeutics market size has reached to $3.55 billion in 2025 • Expected to grow to $4.97 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rise In Prostate Cancer Fueling The Growth Of The Market Due To Increasing Life Expectancy • Market Trend: Innovative Nerve Stimulation Therapy Offers Long-Term Relief For Bladder And Bowel Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Urinary Retention Therapeutics Market?

Urinary retention therapeutics refer to a variety of medical approaches aimed at treating the inability to fully empty the bladder. These treatments focus on relieving bladder pressure, restoring normal urinary flow, and preventing potential complications such as infections or kidney damage. The ultimate goal is to improve bladder function and enhance the patient's overall comfort and quality of life. The main urinary retention therapeutics are 5-alpha-reductase inhibitor and alpha-blocker drugs, anticholinergic or antispasmodic agents, antidepressants, skeletal muscle relaxants, topical estrogens, and others. 5-Alpha-reductase inhibitors and alpha-blocker drugs are medications used primarily to treat benign prostatic hyperplasia (BPH), with the former reducing prostate size by blocking the hormone dihydrotestosterone (DHT) and the latter relaxing muscle fibers in the prostate and bladder neck to improve urine flow. It is used for stress incontinence, urge incontinence, over-flow incontinence, mixed incontinence, and others and is administered through various routes such as oral, intravesical, intravenous, and transdermal. It is distributed through channels including retail pharmacy, hospital pharmacy, and online pharmacy.

What Is The Urinary Retention Therapeutics Market Growth Forecast?

The urinary retention therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.97 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing demand for targeted drug therapies, rising investments in urological research, increasing use of digital patient monitoring, expansion of outpatient therapeutic care, development of next-generation bladder control medications. Major trends in the forecast period include increasing use of combination drug therapies, rising adoption of personalized bladder treatment plans, growing focus on minimally invasive therapeutic options, expansion of novel pharmacological agents, enhanced monitoring of bladder function outcomes.

Global Urinary Retention Therapeutics Market Segmentation

1) By Drug Class: 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs, Anticholinergic Or Antispasmodic Agents, Antidepressants, Skeletal Muscle Relaxants, Topical Estrogens, Other Drugs 2) By Incontinence Type: Stress Incontinence, Urge Incontinence, Over-Flow Incontinence, Mixed Incontinence, Other Incontinence Types 3) By Administration Route: Oral, Intravesical, Intravenous, Transdermal 4) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy Subsegments: 1) By 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs: Finasteride, Dutasteride, Tamsulosin, Alfuzosin, Terazosin, Doxazosin 2) By Anticholinergic or Antispasmodic Agents: Oxybutynin, Tolterodine, Solifenacin, Darifenacin, Trospium, Fesoterodine 3) By Antidepressants: Imipramine, Amitriptyline, Duloxetine 4) By Skeletal Muscle Relaxants: Baclofen, Tizanidine, Diazepam, Cyclobenzaprine 5) By Topical Estrogens: Estradiol Cream, Conjugated Estrogens, Estriol Vaginal Cream 6) By Other Drugs: Botulinum Toxin (Botox), Mirabegron, Desmopressin

What Is The Driver Of The Urinary Retention Therapeutics Market?

The growing cases of prostate cancer are expected to propel the growth of the urinary retention therapeutics market going forward. Prostate cancer refers to a malignant condition characterised by the uncontrolled growth of cells in the prostate gland. The growing incidence is increasing because ageing male populations lead to more men reaching high-risk age brackets. The urinary retention therapeutics supports this growth by providing treatments and devices to manage urinary flow blockages often caused by prostate enlargement or tumour-related urethral obstruction. For instance, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organization, the number of new cases of prostate cancer in the US will increase from 268,490 in 2022 to 288,300 in 2023. The number of deaths due to prostate cancer will also slightly increase, from 34,500 in 2022 to 34,700 in 2023. Therefore, the growing cases of prostate cancer are driving the growth of the urinary retention therapeutics industry.

Key Players In The Global Urinary Retention Therapeutics Market

Major companies operating in the urinary retention therapeutics market are Pfizer Inc. , Merck KGaA , Abbvie Inc. , Bayer AG , Sanofi SA , GlaxoSmithKline Plc. , Medtronic Plc , Boston Scientific Corp. , Sumitomo Pharma Inc. , Ipsen Pharma , Coloplast A/S , Dr. Reddy’s Laboratories , Cipla Limited , Amneal Pharmaceuticals Inc. , Ferring Pharmaceuticals , Astellas Pharma Inc. , Johnson & Johnson , Teva Pharmaceutical Industries Ltd. , Novartis International AG , Takeda Pharmaceutical Company Limited , Boehringer Ingelheim International GmbH , UroGen Pharma Ltd.

Global Urinary Retention Therapeutics Market Trends and Insights

Major companies in the urinary retention therapeutics market are focusing on developing innovative solutions such as sacral nerve stimulators to improve bladder control, enhance patient quality of life, and reduce dependence. A sacral nerve stimulator is a medical device that delivers mild electrical impulses to the sacral nerves near the lower spine to help control bladder and bowel function. For instance, in November 2024, Medtronic plc, an Ireland-based medical technology company, launched the FDA-approved InterStim X Sacral Neuromodulation (SNM) system in India, designed to treat overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention. The therapy works by delivering personalized sacral nerve stimulation, targeting nerve signals that regulate bladder and bowel functions to reduce symptoms like frequent urination and incontinence. The treatment is performed in two stages, starting with a trial phase using an external stimulator followed by implantation of a pulse generator if successful, and the device offers a long battery life of over 10 years without recharging.

What Are Latest Mergers And Acquisitions In The Urinary Retention Therapeutics Market?

In September 2023, Caldera Medical, a US-based women’s health medical device company, acquired Atlantic Therapeutics for an undisclosed amount. With this acquisition, Caldera Medical is set to enhance its women's health portfolio by integrating the FDA-cleared Innova product family, which offers non-invasive treatments for stress urinary incontinence (SUI). Atlantic Therapeutics is an Ireland-based medical technology company that specializes in treatments for bladder control, which aligns with urinary retention therapeutics.

Regional Outlook

North America was the largest region in the urinary retention therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Urinary Retention Therapeutics Market?

The urinary retention therapeutics market consists of revenues earned by entities by providing services such as drug development and formulation services, clinical trial management, regulatory consulting and medical device integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary retention therapeutics market also includes sales of catheters, prostate shrinking agents, urethral stents and sacral neuromodulation devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Urinary Retention Therapeutics Market Report 2026?

The urinary retention therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the urinary retention therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.